By Muhammad Shabbir
Publication Date: September 17, 2026
A compound made by certain gut bacteria after they process compounds found in foods such as pomegranates, walnuts and berries has attracted attention from researchers studying intestinal health.
The compound is called urolithin A, or UroA.
A new study from researchers at the University of Louisville found that UroA can activate a specific biological pathway in intestinal cells that appears to strengthen the gut barrier and support protective immune responses. The research was published in Nature Communications.
The finding is interesting because the pathway involved, called the aryl hydrocarbon receptor (AHR), can produce different effects depending on which cells are affected and how strongly it is activated.
However, there is an important limitation that should not be overlooked.
The research does not show that eating pomegranates, walnuts or berries can treat inflammatory bowel disease (IBD). It also does not establish urolithin A as a treatment for Crohn's disease or ulcerative colitis.
Instead, the study helps explain a biological mechanism that researchers may eventually be able to target therapeutically.
What Is Urolithin A?
Urolithin A is not simply a compound that you get directly from eating a pomegranate.
It is a microbial metabolite, meaning that gut microorganisms can produce it from certain compounds present in foods.
Pomegranates, walnuts and some berries contain substances called ellagitannins and ellagic acid. Gut microbes can metabolize these compounds, and some people may produce urolithin A as a result.
This is one reason the relationship between food and gut health can be more complicated than simply asking whether a particular food is "good" or "bad" for the intestine.
The response can depend partly on the microorganisms living in an individual's digestive tract.
Researchers have previously studied UroA because of its potential biological effects, but the new work focused on a more specific question:
How might UroA influence intestinal cells and the immune system?
Why the Intestinal Barrier Matters
The intestine is more than a tube through which food passes.
Its inner surface contains a specialized layer of epithelial cells that helps separate the contents of the digestive tract from the body's internal environment.
This barrier has several important functions.
It helps:
Control what passes between the intestine and the body
Keep potentially harmful microorganisms contained within the gut
Support communication between intestinal cells and the immune system
Produce protective mucus
Contribute to antimicrobial defense
When intestinal barrier function is disrupted, interactions between gut microbes and the immune system can change.
This is particularly relevant to inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, which involve chronic inflammation of the gastrointestinal tract.
The new study investigated whether UroA could influence some of these protective processes.
The Biological Pathway Researchers Discovered
The most interesting part of the study involves a chain of biological events.
Researchers found that UroA activates AHR in intestinal epithelial cells.
AHR, or aryl hydrocarbon receptor, is a protein that responds to different chemical signals originating from the environment, diet and microorganisms.
But AHR activation does not always produce the same outcome.
The Louisville researchers found that, in intestinal epithelial cells, UroA activation of AHR triggered another pathway involving the NLRP6 inflammasome.
That led to increased release of interleukin-18 (IL-18).
The researchers then connected this process to increased production of interleukin-22 (IL-22), as well as mucin 2 and REG3γ.
In simplified terms, the proposed sequence is:
Urolithin A → AHR → NLRP6 → IL-18 → IL-22 → intestinal protective responses
This pathway is important because it links a compound produced by gut microbes with several mechanisms involved in intestinal barrier function and mucosal immunity.
An Unexpected Role for an Inflammatory Pathway
The word "inflammasome" can sound alarming.
Inflammasomes are involved in inflammatory signaling, and excessive or inappropriate inflammation can contribute to disease.
But inflammation is not automatically harmful.
The immune system uses inflammatory pathways for many normal biological functions, including responding to injury and microorganisms.
In this study, researchers found that activating the NLRP6 inflammasome in intestinal epithelial cells through UroA was associated with a protective response rather than simply promoting damaging inflammation.
The researchers reported that UroA-induced IL-18 was important for downstream IL-22, mucin 2 and REG3γ production and was associated with protection against colitis in experimental models.
This helps illustrate an important principle in biology:
The effect of an immune pathway can depend on where, when and how it is activated.
What Happened in the Experimental Models?
This is where readers need to understand the evidence level.
The study was not a large clinical trial in people with Crohn's disease or ulcerative colitis.
Researchers used several experimental approaches, including:
Mouse intestinal epithelial cells
Experimental models of colitis
Intestinal organoid systems
Human intestinal biopsy samples from people with IBD
The mouse experiments provided evidence that UroA could activate the AHR-NLRP6 pathway and that this signaling was associated with protection against colitis.
The researchers also examined human intestinal tissue.
In samples from patients with IBD, UroA increased IL-18 and IL-22 signaling in relevant intestinal cells.
That human tissue finding is interesting, but it should not be confused with a clinical treatment trial.
No evidence from this study shows that giving urolithin A to people with Crohn's disease or ulcerative colitis improves symptoms, induces remission or prevents complications.
Does Eating Pomegranate Increase Urolithin A?
This is one of the easiest points to misunderstand.
The study concerns urolithin A, which is produced by gut microbes from certain food-derived compounds.
Eating a food containing ellagitannins does not mean that your body will automatically produce a specific amount of UroA.
Gut microbial composition varies considerably between individuals.
As a result, two people could consume similar foods but produce different amounts of microbial metabolites.
Therefore, it would be an overstatement to say:
"Eat pomegranates to produce enough urolithin A to heal your gut."
The study does not establish that.
It instead provides evidence for a biological connection between dietary compounds, microbial metabolism and intestinal signaling.
Could This Lead to New IBD Treatments?
Potentially, but considerably more research is needed.
Current treatments for IBD are designed to control inflammation and maintain remission. Researchers are continually looking for ways to make treatment more precise.
The Louisville study raises the possibility of targeting specific protective pathways in intestinal epithelial cells rather than broadly modifying immune activity.
That could eventually lead to new therapeutic strategies.
But there is a long distance between identifying a biological mechanism and developing an effective treatment.
Researchers would need to determine questions such as:
What dose of UroA would be appropriate?
How is UroA absorbed and metabolized in humans?
Which patients would respond?
How does existing IBD medication affect this pathway?
Can the pathway be activated safely over the long term?
Would purified UroA work differently from food-derived compounds?
Can the findings be reproduced in controlled human clinical trials?
The current study does not answer those questions.
What About "Leaky Gut"?
The term "leaky gut" is frequently used online, but it can mean different things depending on the context.
The scientific concept relevant to this study is intestinal barrier integrity.
The intestinal barrier is a real biological system involving epithelial cells, mucus, immune signaling and interactions with microorganisms.
Researchers found that UroA influenced pathways involved in maintaining this barrier.
That does not mean that every digestive symptom is caused by a "leaky gut," nor does it mean UroA is a proven solution for bloating, gas, abdominal discomfort or other common digestive complaints.
The biological mechanism should not be turned into a diagnosis or a treatment claim.
Does This Mean Urolithin A Is a Gut Supplement?
Not based on this study alone.
Urolithin A is also available commercially as a supplement, but laboratory findings should not automatically be interpreted as evidence that supplementation will treat disease.
The research examined a specific biological mechanism and used experimental models rather than establishing clinical effectiveness for IBD treatment.
If someone has Crohn's disease, ulcerative colitis or another diagnosed gastrointestinal condition, they should not replace prescribed treatment with foods or supplements based on this research.
Why the Gut Microbiome Matters
One of the most interesting implications of the study is that it highlights the relationship between diet, gut microbes and human cells.
A food does not necessarily act directly on the body in its original form.
Sometimes microorganisms in the digestive tract transform food-derived molecules into entirely different compounds.
Those microbial metabolites can then interact with human cells.
In this case, researchers investigated how a microbial metabolite, UroA, interacts with intestinal epithelial cells through AHR and downstream immune signaling.
This represents a more sophisticated way of thinking about nutrition:
Food → gut microbes → microbial metabolites → human cells
The exact outcome can depend on the microbial environment and biological context.
What This Research Does Not Prove
Because the study is receiving attention for its potential implications, it is worth separating established findings from conclusions that remain unproven.
The study does show that researchers identified a UroA-related AHR-NLRP6-IL-18-IL-22 pathway in experimental systems and observed related signaling in human intestinal biopsy samples.
The study does not show that:
Pomegranates cure IBD
Walnuts cure IBD
Berries cure IBD
Urolithin A cures Crohn's disease
Urolithin A cures ulcerative colitis
Everyone produces UroA after eating these foods
UroA supplements are an established IBD treatment
Eating more pomegranate will necessarily strengthen an individual's intestinal barrier
These distinctions matter because promising laboratory findings can take years of research before they become useful clinical treatments.
What Can You Reasonably Take From the Study?
For a healthy person, there is no need to turn this research into a single "gut-healing food."
Instead, the broader lesson is that diet and the microbiome interact in complex ways.
Foods such as fruits, nuts and other plant foods can provide many nutrients and bioactive compounds. But individual responses can vary, and one metabolite should not be viewed as the explanation for overall gut health.
For someone already diagnosed with IBD, the practical takeaway is different.
This research is interesting because it may eventually contribute to more targeted treatments, but it is not a reason to stop prescribed therapy or self-treat an inflammatory bowel condition.
The Bottom Line
Scientists at the University of Louisville identified a mechanism through which urolithin A, a metabolite produced by gut bacteria from certain food-derived compounds, can activate AHR in intestinal epithelial cells and engage the NLRP6-IL-18-IL-22 pathway. The researchers linked this pathway with intestinal barrier protection and protection against colitis in experimental models.
The study also examined human intestinal biopsy samples, providing additional evidence that the pathway is relevant to human IBD biology. However, it was not a clinical trial demonstrating that UroA treats Crohn's disease or ulcerative colitis.
The real significance of the discovery is therefore not that researchers have found a new "cure" in pomegranates or berries.
It is that scientists have identified a potentially important connection between food-derived compounds, gut microbes, intestinal cells and immune signaling.
Future human studies will need to determine whether this pathway can safely and effectively be targeted as part of IBD treatment.
Medical Disclaimer
This article is for general educational purposes only and does not provide individualized medical advice. Urolithin A and foods containing its precursor compounds should not be used as substitutes for prescribed treatment for Crohn's disease, ulcerative colitis or other medical conditions. Speak with a qualified healthcare professional about individual symptoms and treatment decisions.
Sources
Primary research:
Ghosh S, Vanwinkle ZM, Bodduluri SR, et al. Urolithin A activates aryl hydrocarbon receptor-NLRP6-mediated pathways in intestinal epithelial cells to modulate mucosal immunity and strengthen gut barrier integrity. Nature Communications. 2026;17:5411. doi:10.1038/s41467-026-73760-3.
Institutional research summary:
University of Louisville, UofL scientists unlock gut-healing power of fruits and nuts paired with the right gut microbes, June 26, 2026.
Suggested Internal Links
Use these links naturally rather than inserting them merely for SEO:
7-Day Gut Health Reset: Simple Habits That Help Digestion — relevant introductory gut-health content.
Tomato Juice vs. Pomegranate Juice for Blood Pressure — relevant because pomegranate is discussed in the current article.
Spices That May Support Liver Health: What the Evidence Really Shows — useful for your broader evidence-based food/health cluster.
0 Comments